Beckman Coulter, Agencourt Bioscience, Thermo Electron, Solexa | GenomeWeb

Beckman to Buy Agencourt For Up to $140M; Plans New 'Personal Genomics' Spin-Off

Beckman Coulter intends to purchase Agencourt Bioscience for up to $140 million in cash, the companies said this week.

Beckman plans to acquire all of Agencourt's outstanding stock for $100 million in cash and make up to $40 million in contingent payments through 2007. Following the acquisition, which is expected to close near the end of May, Agencourt will become a wholly owned subsidiary of Beckman, and will remain based in Beverly, Mass.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.